Moodle
You are not logged in. (Login)
Skip Check this out...
Show or hide block

Check this out...

Welcome to E-Menai

effects of alcohol and ambien We believe Cambia addresses these needs and will be a valuable addition to physicians' migraine armamentarium. The product is currently marketed by Novartis Pharma AG, via a license from APR, under the trademarks Voltfast or Catafast in several European countries. APR has signed licensing agreements with pharmaceutical companies in 117 countries worldwide effects of alcohol and ambien and its sales are almost totally achieved abroad. The Acurox Tablets NDA was originally accepted for filing by FDA earlier this year with a priority review classification. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act").

.


NewsA Level

MONTGOMERY, Ala. Food and Drug Administration (FDA) has approved Cambia, a diclofenac-based non-steroidal anti-inflammatory drug ("NSAID") combined with potassium bicarbonate, for the treatment of acute migraine with or without aura in adults. Cambia, formulated with KPA's patented Dynamic Buffering Technology (DBT), was specifically developed to address widespread unmet needs among patients by offering fast and effective relief of migraine pain. The company started in 2001 as ProEthic Pharmaceuticals, Inc. A privately held company, KPA focuses its efforts on the acquisition, development, licensing and marketing of pharmaceutical products. It is focused in the R&D of innovative and patented drug delivery systems as well as innovative pharmaceutical products primarily for oral and topical administration..